Flamel Technologies

Flamel Technologies SA
Société Anonyme
Traded as NASDAQ: FLML
Industry Healthcare – Drug Delivery
Founded 1990
Headquarters Lyon, France
Key people

Michael S. Anderson ( Chief Executive Officer and Director)
Sian Crouzet ( Principal Financial Officer and Financial Controller )

Raphael Jorda Ph.D. ( Chief Operating Officer) (Dec 31, 2005)
Revenue $ 22.44M (Dec31, 2013)[1]
Website www.flamel.com

Flamel Technologies SA (NASDAQ:FLML), a specialty pharmaceutical company, was set up in 1990 and now is based in Lyon, France. The company sells therapeutic products under GMP guidelines - audited by the United States Food and Drug Administration (FDA) - through its own drug pipeline platforms, Medusa and Micropump. FDA-audited GMP guidelines in France and United States.[2]

The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.[3][4]

Operations

Flamel Technologies has a strong partnership with GlaxoSmithKline.
In June 2013, Flamel Technologies reached a multi-year partnership agreement with an undisclosed pharmaceutical company, estimating a revenue of over $4 million over the next several years.[5]
In May 2013, Flamel Technologies regained the operating right of two drugs using Trigger Lock® delivery technology.[6]

In 1997, the company completed its acquisition of a pharmaceutical production facility located in Bordeaux, France from SmithKline Beecham (SB), and entered into a production agreement with SB.[7]

Research & development

In September 2013, the US FDA accepted the review of the Flamel Technologies 's second new drug application (NDA) by April 28, 2014 (Prescription Drug User Fee Act (PDUFA) date.[8]
In June 2013, FDA approved the company's Bloxiverz (neostigmine methylsulfate, used for the reversal of the effects of non-depolarizing neuromuscular blocking agents.[9]
In Feb 2013, Flamel Technologies invested a USD$15 million debt financing with Deerfield Management for the company’s R&D projects. The interest rate on the debt was 12.5% and the debt must be repaid over four years. Deerfield Management would also receive a 1.75% royalty on net sales of the project by former Éclat Pharmaceuticals.[10]

Products & services

Flamel Technologies SA produces Micropump-based microparticles (oral drugs), liquid formulations (LiquiTime) and Hycet® (hydrocodone acetaminophen oral solution), and abuse-deterrent formulations (Trigger Lock) drug delivery platforms. Its Medusa is based on a hydrophilic biodegradable polyglutamate chain grafted with hydrophobic Vitamin E. Its DeliVax improves antigen persistence.[11] Its Trigger Lock is used for tamper resistant formulations of narcotics, as well as resistant to alcohol-induced dose dumping.[12]

References

  1. ↑ "Company Key Statistics".
  2. ↑ "Company Business Summary". finance.yahoo.com.
  3. ↑ "About Us". http://www.eclatpharma.com/. Retrieved 29 Dec 2014. External link in |website= (help)
  4. ↑ "Flamel Technologies Announces Acquisition of Éclat Pharmaceuticals". businesswire.com. 14 Mar 2012. Retrieved 29 Dec 2014.
  5. ↑ "Flamel Technologies Announces Product Partnership Agreement". www.reuters.com.
  6. ↑ "Flamel Technologies Obtains Rights to Two Molecules of Trigger Lock Product Line".
  7. ↑ "Flamel Technologies S.A. Closes Acquisition of French Pharmaceutical Production Facility from SmithKline Beecham". www.thefreelibrary.com.
  8. ↑ "Flamel Technologies Announces Acceptance of FDA Review for Second NDA".
  9. ↑ "Flamel Technologies Announces FDA Approval of Bloxiverz".
  10. ↑ "Announces Appointment of Gregg Stetsko as Vice President, Research & Development".
  11. ↑ "Company Full Description". www.reuters.com.
  12. ↑ "Company Full Description". www.flamel.com.

External links

This article is issued from Wikipedia - version of the 2/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.